The present study also provided the first evidence that pemafibrate decreases the serum level of sDPP-4/CD26 as much as weight loss, together with a significant improvement of liver enzymes (ALT and GGT) in patients with type 2 diabetes and MASLD. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.